Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907581 | 0.87 | TP53 (0.33) | TP53GAADUTFKBP1A | |
| SCHEMBL13871611 | 0.81 | KDM4E (0.31) | GAADUT | |
| SCHEMBL4304524 | 0.80 | FKBP1A (0.30) | FKBP1A | |
| SCHEMBL2211707 | 0.80 | ALDH1A1 (0.39) | GAA | |
| SCHEMBL4300107 | 0.78 | HRH1 (0.42) | TP53CYP1A2 | |
| SCHEMBL4551977 | 0.78 | HRH1 (0.42) | TP53CYP1A2 | |
| SCHEMBL4106475 | 0.74 | PTGER4 (0.34) | — | |
| SCHEMBL961203 | 0.73 | DUT (0.33) | DUTFKBP1A | |
| SCHEMBL4301619 | 0.72 | CYP4F2 (0.41) | FKBP1A | |
| SCHEMBL3679333 | 0.70 | PDK2 (0.34) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | TP53 4631/4885GAA 3844/4885CYP1A2 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.